Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a confirmed diagnosis of prostate cancer based on a tissue sample (biopsy).
- People whose prostate cancer is still responding to hormone therapy that lowers testosterone (known as castration-sensitive prostate cancer).
- People with a limited number of areas where cancer has spread — specifically, no more than 3 spots seen on standard CT and bone scans, or no more than 5 spots seen on a more detailed PET scan. The spread must be limited to bones (including the spine) and/or lymph nodes.
- People who have given their written agreement to take part in the trial.
- People whose blood counts, liver function, and kidney function meet the required levels as measured by blood tests (confirm specific values with trial site).
Who may not be able to join:
- People who do not have a confirmed tissue-based diagnosis of prostate cancer.
- People whose prostate cancer has stopped responding to hormone therapy (known as castration-resistant prostate cancer).
- People with cancer that has spread to more areas than the trial allows — 3 or more spots on standard CT/bone scan, or 5 or more spots on a PET scan.
- People whose cancer has spread to internal organs such as the liver or lungs (called visceral metastases).
- People whose primary tumour is classified as stage T4, meaning it has grown into nearby structures (confirm with trial site).
- People who have previously been treated with certain chemotherapy (docetaxel), certain advanced hormone therapies (such as apalutamide, abiraterone with prednisone, or enzalutamide), or bone-strengthening medications.
- People who need urgent surgery or radiation treatment for their metastatic disease right away.
- People whose cancer spots in the body cannot be safely treated with the specialised type of radiation (SBRT) used in this trial, due to the location or size of the lesions.
- People who have or have had another cancer that is not currently under control, except for a common type of non-invasive skin cancer (basal cell carcinoma).
- People with certain heart conditions, metabolic disorders, bowel disease, or other health conditions that may make the treatments used in this trial unsafe (confirm with trial site).
- People who are unable to give informed consent, or from whom consent has not been obtained.
- People who are currently participating in another clinical trial, or who have done so within the past 3 months.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Antonio J Conde Moreno, MD PhD, Grupo de Investigación Clínica en Oncología Radioterápica
Phone: +34 649039866
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Radiological progression-free survival (rPFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.